CNS Archives -

Global Gene’s Craig Martin introduces a new patient identification initiative that strives to improve diagnosis and access to

It’s time to do better for patients with rare neurological disorders

https://pharmaphorum.com/patients/global-genes-rare-neurological-disorder-research/

Digital/ Events/ Events

3rd Annual Blood-Brain Barrier Summit

sophie ellis blood-brain barrier, CNS, conference, drug delivery, neuroscience 0 Comment

Enhance Drug Delivery Across the Blood-Brain Barrier

3rd Annual Blood-Brain Barrier Summit

https://pharmaphorum.com/events/3rd-annual-blood-brain-barrier-summit/

Digital/ Partner content/ Press releases

The 3rd Annual Blood-Brain Barrier Summit Returns in August 2021

sophie ellis blood-brain barrier, CNS, conference, drug delivery, neuroscience 0 Comment

Specialized Digital Conference for Biopharma

The 3rd Annual Blood-Brain Barrier Summit Returns in August 2021

https://pharmaphorum.com/partner-content/the-3rd-annual-blood-brain-barrier-summit-returns-in-august-2021/

Events/ Events/ R&D

2nd Gene Therapy for Neurological Disorders Europe

Ellie Saunders Alzheimer's, CNS, gene therapy, neurological disorders, Parkinson's 0 Comment

Maximising the Opportunity in CNS Gene Therapies

2nd Gene Therapy for Neurological Disorders Europe

https://pharmaphorum.com/events/2nd-gene-therapy-for-neurological-disorders-europe/

Sales and Marketing/ Views & Analysis/ Views and analysis

Nine for 2021: Addressing the pandemic legacy

mike.hammerton@pharmaphorum.com 2021, biologics, biosimilars, China, CNS, customer engagement, Nine for 2021 0 Comment

In this second ‘Nine for 2021‘ article, IQVIA’s Sarah Rickwood looks at four issues which will directly impact

Nine for 2021: Addressing the pandemic legacy

https://pharmaphorum.com/views-analysis-sales-marketing/nine-for-2021-pandemic-legacy/

Market Access/ News/ News

US, EU reviews start for Novartis’ Ocrevus rival ofatumumab

Phil Taylor CNS, multiple sclerosis, Novartis, Ocrevus, Roche 0 Comment

Novartis’ cancer therapy ofatumumab has moved closer to its second life as a treatment for multiple sclerosis, with

US, EU reviews start for Novartis’ Ocrevus rival ofatumumab

https://pharmaphorum.com/news/us-eu-reviews-start-for-novartis-ocrevus-rival-ofatumumab/

R&D/ Views & Analysis/ Views and analysis

Finding the big picture for Alzheimer’s

George Underwood Alzheimer's, CNS, dementia, Oskar Fischer Prize 0 Comment

The $4m Oskar Fischer Prize hopes to catalyse a breakthrough in Alzheimer’s research by encouraging a ‘big picture’

Finding the big picture for Alzheimer’s

https://pharmaphorum.com/r-d/views-analysis-r-d/finding-the-big-picture-for-alzheimers/

R&D/ Views & Analysis/ Views and analysis

A bright future for CNS and Alzheimer’s?

George Underwood Alzheimer's, amyloid, Asceneuron, CNS, progressive supranuclear palsy, Tau 0 Comment

Swiss biotech Asceneuron is developing what could be the first treatment for progressive supranuclear palsy (PSP), a rare

A bright future for CNS and Alzheimer’s?

https://pharmaphorum.com/r-d/views-analysis-r-d/a-bright-future-for-cns-and-alzheimers/

News/ News/ R&D

Regeneron and Alnylam announce $1bn collaboration

George Underwood Alnylam, CNS, eye, liver, Regeneron 0 Comment

Regeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and

Regeneron and Alnylam announce $1bn collaboration

https://pharmaphorum.com/news/regeneron-and-alnylam-announce-1bn-collaboration/

Trending

CNS

Login